Searchable abstracts of presentations at key conferences in endocrinology

ea0031oc5.2 | Pituitary and neoplasia | SFEBES2013

The role of microRNA miR-34a in the regulation of aryl hydrocarbon receptor interacting protein

Denes Judit , Kasuki Leandro , Trivellin Giampaolo , Gadelha Monica , Korbonits Marta

Germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene predispose to early onset pituitary adenoma, with a preponderance of somatotrophinomas. Patients harbouring an AIP mutation respond poorly to somatostatin analogue (SSA) treatment. On the other hand, a subset of sporadic somatotrophinomas with no AIP mutations show low AIP protein expression and exhibit a decreased response to SSA treatment as well. microRNAs are small...

ea0063gp57 | Acromegaly and GH | ECE2019

Biochemical control was sustained with long-acting pasireotide in patients with uncontrolled acromegaly over continued treatment with first-generation somatostatin analogues (SSAs): Results from the extension of phase 3b, open-label study

Gadelha Monica , Colao Annamaria , Bex Marie , Mukherjee Rishav , Bourad Catherine , Maamari Ricardo , Raverot Gerald

Background: In a phase 3b, open-label study (NCT02354508) assessing efficacy and safety of long-acting pasireotide in patients with uncontrolled acromegaly after ≥3 months of treatment with first-generation SSAs, 18/123 (15%) patients achieved the primary endpoint of mean growth hormone (mGH) <1.0 μg/l and insulin-like growth factor-1 (IGF-1) <ULN (upper limit of normal) at week 36. Here, we present the results from the extension phase of this study.<p c...

ea0037ep808 | Pituitary: clinical | ECE2015

Trial design of phase IIIb, open-label, single arm study to evaluate efficacy and safety of pasireotide LAR in patients with inadequately-controlled acromegaly despite treatment with first-generation somatostatin analogues

Gadelha Monica R , Pedroncelli Alberto M , Kandra Albert , Resendiz Karina Hermosillo , Colao Anna Maria

Introduction: The present study is designed to evaluate the efficacy and safety of pasireotide-long-acting release (LAR) in patients with acromegaly inadequately controlled after &gE;3 mo treatment with the maximal approved doses of first-generation SSAs.Methods: Phase IIIb, multicentre, single-arm, open-label study.Patients: Adults (N~112) with inadequately controlled acromegaly (mean GH>1 μg/l and IGF-1>1.3xULN) desp...

ea0032p867 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Real world data in acromegaly – a retrospective chart audit

Ferone Diego , Forsythe Anna , Ludlam William , Rondena Roberta , Thomas Cherry , Gadelha Monica

Introduction: The ideal strategy and the role of the different therapeutic options in acromegaly remain unclear. This research focuses on observing treatment options, and the respective level of disease control in acromegaly.Methods: A retrospective chart audit was conducted in US, France, Italy, and Brazil (September 2012). 97 endocrinologists completed structured case report forms for the 4 most recently-seen patients (two with somatostatin analogues (...

ea0026p263 | Pituitary | ECE2011

Octreotide pharmacokinetics and biochemical control of acromegaly using a subcutaneous octreotide hydrogel implant

Chieffo C , Ryan M , Bai S , Hu X , Decker S , Quandt H , Frohman L , Gadelha M

Two randomized open-label, phase II studies evaluated an octreotide hydrogel implant to suppress serum GH and IGF1 levels in adult acromegaly patients. Implants were inserted subcutaneously in the upper arm for 6 months. Patients in study 1 received 1 (n=5) or 2 (n=6) 52-mg octreotide (60 mg octreotide acetate) hydrated implants; patients in study 2 received a hydrated (H) or nonhydrated (NH) 84-mg octreotide acetate implant (n=34, 1 excluded from efficacy...

ea0056p867 | Pituitary - Clinical | ECE2018

Clinical and mri findings among 120 patients with macroproprolactinemia: results from a retrospective study

Vilar Lucio , Vilar Clarice , Albuquerque Luciano , The Ana Carolina , Trovao Erik , Gadelha Patricia , Lyra Ruy

Background: Macroprolactinemia is a condition where more of 60% of circulating PRL is made up of macroprolactin. It may be observed in both sexes (although women represent about 90% of published cases), and at all ages. As macroprolactin has low biological active and low bioavailibility, most patients are asymptomatic. The Endocrine Society guidelines recommend screening for macroprolactin only in asymptomatic hyperprolactinemic patients. However, some data from the literature...

ea0081p432 | Pituitary and Neuroendocrinology | ECE2022

A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly

Fleseriu Maria , Zhang Zhaoyun , Hanman Kate , Haria Keval , Houchard Aude , Khawaja Sheila , Ribeiro-Oliveira Antonio , Gadelha Monica

Background: Acromegaly is a rare disorder characterized by excess growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Extended dosing intervals (EDIs) of pharmacological treatments may reduce patient burden and costs compared with standard dosing. This systematic literature review (SLR) investigated treatment of acromegaly at EDIs.Methods: MEDLINE/Embase/the Cochrane Library (2001–June 2021) and key congresses (2018–2021) were searche...

ea0063p1093 | Pituitary and Neuroendocrinology 3 | ECE2019

Medical treatment of cushing’s disease during pregnancy with Ketoconazole and Cabergoline – Report of 3 cases

Vilar Lucio , Vilar Clarice , Albuquerque Luciano , Gadelha Patricia , The Ana Carolina , Trovao Erik , Sampaio Icaro , Ferreira Liana , Lyra Ruy

Abstract: Cushing’s syndrome (CS) during pregnancy is a rare condition with fewer an 200 cases reported in the literature, However, because CS results in increased fetal and maternal complications, its early diagnosis and treatment are critical. During pregnancy, 40-50% of cases are caused by adrenal adenomas, while Cushing’s disease (CD) accounts for only one third of the cases. We describe here 3 patients with CD who needed to be treated during pregnancy.<p cla...

ea0063p1113 | Pituitary and Neuroendocrinology 3 | ECE2019

The impact of clomiphene citrate as add-on therapy in male acromegalic patients non-responsive to combined medical therapy

Vilar Lucio , Vilar Clarice , Albuquerque Luciano , Trovao Erik , The Ana Carolina , Gadelha Patricia , Campos Renata , Cardoso Izabela , Borges Thaise , Lyra Ruy

Introduction: Clomiphene citrate (CC), a selective estrogen receptor modulator that increases LH and FSH secretion, improves hypogonadism and fertility outcomes. Moreover, there is limited evidence that it may also be helpful as add-on therapy to normalize IGF-1 levels in male acromegalic patients.Objective: To assess the effect impact of CC on serum IGF-1 and testosterone levels in male acromegalic patients not controlled by the combination of lanreotid...